Godavari Biorefineries Jumps 5% to ₹303.42 After Securing Chinese Cancer Drug Patent

Mumbai, Jul 16, 2025 – Godavari Biorefineries Ltd (NSE: GODAVARIB, BSE: 544279) surged 5% to ₹303.42 at 2:42 PM IST. This is followed by the company’s announcement of the grant of a key cancer treatment patent by Chinese authorities.

Stock Movement

• Adjusted P/E: 549.61
• 52-Week Range: ₹145.00 – ₹408.60
• Market Cap: ₹1,552.78 Cr

Strategic Announcement

As per the disclosure dated July 15, 2025, under Regulation 30 of SEBI LODR, the company confirmed that the China National Intellectual Property Administration (CNIPA) has granted a patent titled: “5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER”.

This patent covers a novel class of compounds that showed strong inhibitory effects on cancer and cancer stem cells in in-vitro studies. The compounds have demonstrated efficacy against multiple cancer types including breast and prostate cancers.

Management Commentary

“This is a significant milestone in our oncology research. The approval strengthens our intellectual property portfolio and opens doors to opportunities in global pharma markets,” the company noted in its filing signed by Manoj Jain, Company Secretary.

Strategic Outlook

This development marks a pivotal step for Godavari Biorefineries in its diversification beyond bio-based chemicals into the high-margin pharmaceutical space. The international recognition from CNIPA enhances the company’s R&D credibility and may offer monetization opportunities through licensing or partnerships in China.

Godavari Biorefineries Stock Performance

As of 2:42 PM IST, Godavari Biorefineries shares are trading at ₹303, up ₹14.44, representing a 5% gain as of July 16, 2025. Godavari Biorefineries shares have declined 11% over the last year, 4.4% year-to-date, and increased 10% in the previous month.

About Godavari Biorefineries

Godavari Biorefineries Ltd, listed on NSE and BSE since October 30, 2024, operates in the Diversified FMCG sector. The company has transitioned from a traditional bio-refinery player into one engaged in specialty chemicals and innovation-led platforms, with a focus on renewable, sustainable inputs and now, novel pharmaceutical compounds.

REF: https://nsearchives.nseindia.com/corporate/GODAVARIBIO_15072025175703_Intimation_to_SE.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations